argenx SE (XBRU:ARGX) Debt-to-Equity

: 0.01 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

argenx SE's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €4 Mil. argenx SE's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €14 Mil. argenx SE's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €3,757 Mil. argenx SE's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for argenx SE's Debt-to-Equity or its related term are showing as below:

XBRU:ARGX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.01
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of argenx SE was 0.01. The lowest was 0.00. And the median was 0.01.

XBRU:ARGX's Debt-to-Equity is ranked better than
99.91% of 1073 companies
in the Biotechnology industry
Industry Median: 0.14 vs XBRU:ARGX: 0.01

argenx SE Debt-to-Equity Historical Data

The historical data trend for argenx SE's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.01

argenx SE Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																-	N/A	-	N/A	0.01

Competitive Comparison

For the Biotechnology subindustry, argenx SE's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

argenx SE Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, argenx SE's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where argenx SE's Debt-to-Equity falls into.

argenx SE Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

argenx SE's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.26	+	14.08)	/	3757.414
	=	0.00

argenx SE's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.26	+	14.08)	/	3757.414
	=	0.00

argenx SE (XBRU:ARGX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

argenx SE Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of argenx SE's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE (XBRU:ARGX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (XBRU:ARGX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ARGX:USA ARGX:Mexico ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.